🔗 Share this article

The first new treatments for gonorrhoea in a generation are being hailed as a "major milestone" in the effort against superbug strains of the bacteria, according to researchers.

An International Public Health Issue

Gonorrhoea infections are escalating worldwide, with data suggesting over 82 million new cases annually. Particularly high rates are observed in Africa and countries within the World Health Organization's Western Pacific region, which includes China and Mongolia to New Zealand. In England, cases have hit a historical peak, while infection numbers across Europe in 2023 were three times higher compared to those in 2014.

“The authorization of new treatments for gonorrhoea is an important and timely development in the reality of increasing worldwide cases, escalating drug resistance and the highly restricted therapeutic options currently available.”

Medical experts are particularly alarmed about the increase in antibiotic-resistant strains. The WHO has listed it as a "high-priority threat". Recent surveillance found that resistance to standard treatments like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

Two New Treatment Options Receive Clearance

Zoliflodacin, also known as Nuzolvence, was cleared by the US FDA in mid-December for combating gonorrhoea. This infection can lead to significant complications, including the inability to conceive. Experts believe that focused deployment of this new drug will help slow the spread of drug resistance.

Gepotidacin, created by the drugmaker GlaxoSmithKline, gained clearance in close succession. This medication, which is employed against UTIs, was shown in trials to be successful in treating drug-resistant strains of the gonorrhoea bacteria.

An Innovative Development Model

Zoliflodacin stemmed from a innovative non-profit model for antibiotic development. The non-profit organisation GARDP collaborated with the pharmaceutical company Innoviva to bring it to fruition.

“This approval marks a major breakthrough in the management of superbug gonorrhoea, which up to this point has been evolving faster than medical innovation.”

Testing Data and Global Access

According to results published in a prominent scientific publication, the new drug eradicated over nine in ten of cases of the STI. This puts it on an similar efficacy with the existing first-line therapy, which combines an injection and a pill. The research included over 900 participants from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Under the terms of its collaboration, the non-profit has the authority to make available and distribute the drug in numerous low-income and middle-income countries.

Doctors directly involved have shared hope. The availability of a single-dose, oral treatment of this kind is seen as a "critical tool" for managing the epidemic. This is viewed as essential to lessen the impact of the illness for patients and to stop the proliferation of highly drug-resistant gonorrhoea worldwide.